Compare DexCom, Inc. (DXCM) vs Figs Inc (FIGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Figs Inc — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Figs Inc trades at $14.96 (market cap $2.49B). The key difference: DexCom, Inc. is far larger — about 12.8× Figs Inc's market cap, and Figs Inc is more actively traded (5,964,311 versus 3,607,070). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Figs Inc for 33 Days on average.
| DXCM | FIGS | |
|---|---|---|
Market Cap | $31.86B | $2.49B |
Volume | 3,607,070 | 5,964,311 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $17.12 |
52-Week Low | $54.84 | $6.90 |
Typical Hold Time | 62 Days | 33 Days |
Enterprise Value | $31.32B | $2.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
FIGS trades at $14.06, down 0.28% today, with a bullish technical signal from moving averages. The company shows strong revenue growth from $556M in 2024 to $631M in 2025, with net income surging to $34M. Recent quarters have consistently beaten EPS expectations, and international sales grew 67% in Q2 2026. Analyst consensus is bullish with a $18.00 price target suggesting 28% upside potential from current levels.
The outlook remains positive with accelerating growth and margin expansion, though the stock's rich valuation (P/E 42.6) presents risk if execution falters. Key catalysts include continued international expansion and sustained demand from healthcare professionals, while risks include premium valuation pressure and competitive threats in medical apparel.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →
